Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidine

Source: Bausch + Lomb

Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness.

“With the availability of Lumify, consumers now have an innovative, over-the-counter treatment option that can help relieve red, irritated eyes within a minute and offer up to eight hours of redness reduction,” Joseph C. Papa, chairman and CEO, Valeant, said in a company news release. “Lumify is unlike other redness relievers on the market and will provide consumers a new welcomed alternative.”

In clinical trials, Lumify eye drops demonstrated 95% improvement at 1 minute with significant results lasting up to 8 hours.  A recent in-home-use-study with over 300 participants also resulted in a 95% satisfaction rating for the product.

“Lumify eye drops deliver a safe and effective redness relieving OTC option that my patients have been asking for,” said Paul Karpecki, OD, FAAO, director of Corneal Services at Kentucky Eye Institute. “I am excited to introduce these new eye drops into my practice and offer my patients long-lasting symptom relief without the adverse effects commonly associated with other redness relievers.”

Lumify is available for purchase at major retailers nationwide, including Walgreens, CVS, Rite Aid, Walmart, Target and Amazon. The bottles, available in 2.5 mL and 7.5 mL sizes, have suggested retail prices of $14.99 and $25.99, respectively.

The brimonidine tartrate ophthalmic solution 0.025% product was licensed by Eye Therapies Inc. to Bausch & Lomb or its affiliates.

For more information, visit www.LumifyEyeDrops.com.

Related Content